NASDAQ$TRVN
Trevena Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported a net loss for Q2 2024, with focus on OLINVYK commercialization and pipeline advancement.
Trevena reported a net loss of $17.1 million for the second quarter of 2024. The company is focusing on the commercialization of OLINVYK and advancing its pipeline, including TRV027 for acute lung injury and TRV250 for acute migraine.
- Net loss for Q2 2024 was $17.1 million, compared to $13.9 million for Q2 2023.
- OLINVYK net revenue was $0.8 million for Q2 2024, compared to $0.4 million for Q2 2023.
- Research and development expenses were $7.0 million for Q2 2024, compared to $7.3 million for Q2 2023.
- Cash and cash equivalents totaled $36.5 million as of June 30, 2024.
Headline financials
Revenue & EPS history
Trevena · Revenue · Quarterly
$325K
Revenue by segment
Trevena · $69K total across 1 segment · Q4 2020
- Product Revenue$69K—100.0%
Forward guidance
Trevena is focused on driving OLINVYK commercialization and advancing its pipeline programs. The company believes its current cash and cash equivalents are sufficient to fund operations into the third quarter of 2025.
Tailwinds
- Focus on OLINVYK commercialization to drive revenue growth.
- Advancing TRV027 for acute lung injury, with potential for significant impact.
- Progressing TRV250 for acute migraine, addressing a large market.
- Sufficient cash to fund operations into the third quarter of 2025.
- Exploring potential partnerships to maximize the value of its assets.
Headwinds
- Continued net losses and dependence on future financing.
- Uncertainties regarding the commercial success of OLINVYK.
- Risks associated with clinical development and regulatory approvals.
- Competition from other pharmaceutical companies.
- Potential impact of economic conditions on healthcare spending.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-2.3%
Avg return
Earnings day
-1.7%
Avg return
5 days after
-10.7%
Avg return
30 days after
44%
20 / 45 earnings
Positive
+15.1%
Q2 2020
Best reaction
-43.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2024 | +9.3% | +12.2% | -5.1% | |
| Q2 2024 | -16.0% | +6.2% | +32.5% | |
| Q1 2024 | -19.4% | -9.3% | -16.5% | |
| Q4 2023 | -19.4% | -9.3% | -16.5% | |
| Q4 2025 | +0.0% | -9.3% | -16.5% | |
| Q3 2023 | -1.5% | -3.2% | +1.0% | |
| Q2 2023 | +3.1% | +3.4% | -20.9% | |
| Q1 2023 | +2.9% | +14.1% | -7.4% | |
| Q4 2022 | -4.1% | +0.4% | -11.2% | |
| Q3 2022 | -43.9% | -33.0% | -50.0% | |
| Q2 2022 | +6.3% | +5.0% | -12.9% | |
| Q4 2021 | +13.8% | +4.1% | -32.7% | |
| Q1 2022 | +13.8% | +4.1% | -32.7% | |
| Q3 2021 | -17.1% | -21.2% | -25.9% | |
| Q2 2021 | -8.6% | -15.0% | -10.7% | |
| Q1 2021 | +2.8% | +3.9% | -5.0% | |
| Q4 2020 | -5.9% | +5.4% | -12.2% | |
| Q3 2020 | -6.5% | -8.8% | -8.4% | |
| Q2 2020 | +15.1% | -2.1% | -26.9% | |
| Q1 2020 | +4.0% | +21.0% | +45.4% | |
| Q4 2019 | -5.7% | -14.4% | -41.4% | |
| Q3 2019 | -20.4% | -23.9% | -32.1% | |
| Q2 2019 | +3.3% | +0.5% | -1.1% | |
| Q1 2019 | -9.0% | -13.5% | -32.3% | |
| Q4 2018 | -0.7% | +13.6% | +3.4% | |
| Q3 2018 | +7.2% | +10.0% | +2.6% | |
| Q2 2018 | +10.1% | +8.8% | +21.6% | |
| Q1 2018 | +8.2% | -3.4% | -13.0% | |
| Q4 2017 | +2.0% | -5.0% | -19.3% | |
| Q3 2017 | -2.7% | +18.7% | -4.7% | |
| Q2 2017 | -2.8% | -2.0% | -4.0% | |
| Q1 2017 | -4.1% | -6.2% | -24.8% | |
| Q4 2016 | -8.3% | -3.5% | -17.0% | |
| Q3 2016 | -8.3% | -8.8% | +19.1% | |
| Q2 2016 | +0.1% | +2.5% | -0.1% | |
| Q1 2016 | +3.3% | — | — | |
| Q4 2015 | -13.9% | — | — | |
| Q3 2015 | +1.5% | — | — | |
| Q2 2015 | +6.7% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | +8.5% | — | — | |
| Q3 2014 | -0.9% | — | — | |
| Q2 2014 | +0.5% | — | — | |
| Q1 2014 | -1.7% | — | — | |
| Q4 2013 | -7.0% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro